sanfran 2

NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

Saturday, November 16, 2019

7:30am – 5:00pm 

7.50 AMA PRA Category 1 Credits.™

7.50 Nursing Continuing Professional Development Contact Hours

REGISTER HERE

Location

Mission Bay Conference Center at UCSF

1675 Owens Street

San Francisco, CA 94158

Providers

Jointly Provided by The University of California San Francisco - Helen Diller Family Comprehensive Cancer Center

Course Director

Thomas Hope, MD, University of California San Francisco

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time-consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

7:30-8:00 am Registration & Breakfast

8:00 am Welcome and Opening RemarksThomas Hope, MD, UCSF

Overview of Neuroendocrine Tumors

  • 8:00 am – 8:30 am Introduction and Overview of NETs – Thomas Hope, MD, UCSF
  • 8:30 am – 8:50 am New Classifications Systems of NENs – Nancy Joseph, MD, UCSF
  • 8:50 am – 9:10 am Imaging in NETs – Thomas Hope, MD, UCSF

Management of GI, Pancreas, and Lunt NETs

  • 9:10 – 9:30 am   Management of Mid Gut NETs – Emily Bergsland, MD, UCSF
  • 9:30 – 9:50 am   Management of pancreatic NETs – Pamela Kunz, MD, Stanford Cancer Center
  • 9:50 – 10:10 am Management of Bronchial NETs – Sukhamani Padda, MD, Stanford University

10:10 – 10:30 am Break

Peptide Receptor Radionuclide Therapy (PRRT)

  • 10:30 – 11:00 am PRRT – Martin Auerbach, MD, UCLA
  • 11:00 – 11:15 am Managing PRRT Related Symptoms and Treatment Logistics – Sheila Lindsay, NP, UCSF
  • 11:15 – 11:50 pm Tumor Board Cases: Medical Management and PRRT

11:50 – 12:50 pm LUNCH

Surgical Management and Liver Dominant Disease

  • 12:50 – 1:05 pm Role of Surgical Management in NETs – Eric Nakakura, MD, UCSF
  • 1:05 – 1:20 pm Precision Surgery in NETs – Electron Kebebew, MD, Stanford University
  • 1:20 – 1:35 pm LDT in the Era of PRRT – Nicholas Fidelman, MD, UCSF
  • 1:35 – 2:00 pm Tumor Board Cases: Liver Dominant Disease in ET

2:00 - 2:15 pm Break

Symptom Management, Survivorship and Support for NETs Patients

  • 2:15 – 2:30 pm Optimizing Quality of Life and Managing Disease Related Toxicity – Angela Laffan, NP
  • 2:30 – 2:45 pm Managing Carcinoid Heart Disease – Rajni Rao, MD
  • 2:45 – 3:00 pm Diagnosis and Management of Genetic Syndromes Associated with NETs – Maren Scheuner, MD
  • 3:00 – 3:10 pm The Integral Role of Patient Support Groups – Josh Mailman, NorCal CarciNET

3:10 - 3:30 pm Break

Special Topics

  • 3:30– 3:45 pm Advances in the Surgical Management of Para/Pheo – Julie Ann Sosa, MD, UCSF
  • 3:45 – 4:00 pm Management of Para/Pheo – Chienying Liu, MD, UCSF
  • 4:00 – 4:15 pm Work-Up and Treatment of High-Grade Extrapulmonary NEC – Emily Bergsland, MD, UCSF

Tumor Board

  • 4:15 - 5:00 pm Tumor Board: Bringing It All Together

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The CMEsolutions designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits.™  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is awarded 7.5 contact hours.This activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and North American Neuroendocrine Tumor Society.

REGISTER

In-person registration is available onsite the day of the program and will be accommodated on a space-available basis

Registration fee:

NANETS Member

$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before November 10, 2019. On or after November 11, 2019, no refund will be made.

The University of California San Francisco - Helen Diller Family Comprehensive Cancer Center and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.